Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.2K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

159
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
159
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

177
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
177

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practice patterns of DOAC high-intensity period following parenteral lead-in treatment for venous thromboembolism.

Journal of thrombosis and thrombolysis·2026
Same author

Implementation evaluation of an inpatient digital dashboard for direct oral anticoagulant surveillance.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Surgical and procedural bleed risk stratification for anticoagulated patients undergoing planned surgery: commentary on guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Long-Term Outcomes of a Multicenter Aspirin Deprescribing Intervention.

JAMA network open·2026
Same author

2026 American Association for Thoracic Surgery Expert Consensus Document: Diagnosis and management of heparin-induced thrombocytopenia in patients who undergo cardiac surgery.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Prescribing patterns and clinician preferences for direct oral anticoagulant use in unusual site venous thromboembolism: a cross-sectional analysis from the Direct oral anticoagulants in Unusual Site venous Thromboembolism (DUST) study.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Dec 11, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K

COVID-19 versus HIT hypercoagulability.

Theodore E Warkentin1, Scott Kaatz2

  • 1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Hamilton Regional Laboratory Medicine Program (Transfusion Medicine), Hamilton, Ontario, Canada; Service of Clinical Hematology, Hamilton Health Sciences (Hamilton General Hospital), Canada.

Thrombosis Research
|August 26, 2020
PubMed
Summary
This summary is machine-generated.

COVID-19 significantly increases thrombosis risk, especially in severe cases. Vigilance for heparin-induced thrombocytopenia is crucial due to frequent heparin use in managing COVID-19 associated hypercoagulability.

Keywords:
COVID-19Disseminated intravascular coagulationHeparinThrombocytopeniaThrombosis

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

920
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

9.9K

Related Experiment Videos

Last Updated: Dec 11, 2025

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

920
Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow
09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

9.9K

Area of Science:

  • Hematology
  • Critical Care Medicine
  • Infectious Diseases

Background:

  • COVID-19 is associated with a high incidence of thrombosis, affecting both venous and arterial systems.
  • Patients with severe respiratory complications requiring intensive care are particularly at risk.
  • Observed hematological abnormalities in COVID-19 patients often predict adverse outcomes.

Purpose of the Study:

  • To compare and contrast COVID-19-associated hypercoagulability with heparin-induced thrombocytopenia (HIT).
  • To discuss the challenges in recommending thromboprophylaxis and treatment given limited observational data.
  • To emphasize the need for HIT surveillance in COVID-19 patients receiving heparin therapy.

Main Methods:

  • Review and comparison of existing literature on COVID-19 and thrombosis.
  • Analysis of hematological parameters in COVID-19 patients.
  • Discussion of heparin use and HIT risk in the context of COVID-19.

Main Results:

  • COVID-19 presents a wide spectrum of thrombotic events, including unusual presentations.
  • Numerous hematological abnormalities are linked to poor prognosis in COVID-19.
  • Heparin use necessitates monitoring for HIT due to overlapping clinical presentations.

Conclusions:

  • COVID-19 induces a hypercoagulable state with significant thrombotic risks.
  • Differentiating COVID-19 thrombosis from HIT is clinically challenging.
  • Close monitoring for HIT is essential in COVID-19 patients treated with heparin.